{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:11:21Z","timestamp":1790928681080,"version":"4.1.0"},"reference-count":38,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010628","name":"Universidad de La Sabana","doi-asserted-by":"publisher","award":["(Contract No. 906\/2019) call number 850-2019 \u201cCall for the strengthening of CTel projects in Medi-cal and Health Sciences with young talent and regional impact\u201d\u2014MED-228-2018"],"award-info":[{"award-number":["(Contract No. 906\/2019) call number 850-2019 \u201cCall for the strengthening of CTel projects in Medi-cal and Health Sciences with young talent and regional impact\u201d\u2014MED-228-2018"]}],"id":[{"id":"10.13039\/501100010628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Therapeutic drug monitoring (TDM) and continuous infusion strategies are effective interventions in clinical practice, but these practices are still largely unknown in Colombia, especially in the critical care setting. This study aims to describe the practices involved in the administration and TDM of \u03b2-lactams and vancomycin reported by specialists in critical care in Colombia and to explore the factors that are related to the use of extended infusion. An online nationwide survey was applied to 153 specialists, who were selected randomly. A descriptive, bivariate analysis and a logistic regression model were undertaken. In total, 88.9% of the specialists reported TDM availability and 21.57% reported access to results within 6 h. TDM was available mainly for vancomycin. We found that 85.62% of the intensivists had some type of institutional protocol; however, only 39.22% had a complete and socialized protocol. The odds of preferring extended infusions among those who did not have institutional protocols were 80% lower than those with complete protocols, OR 0.2 (95% CI: 0.06\u22120.61). The most important perceived barriers to performing continuous infusions and TDM were the lack of training and technologies. This pioneering study in Colombia could impact the quality of care and outcomes of critically ill patients in relation to the threat of antimicrobial resistance.<\/jats:p>","DOI":"10.3390\/pharmaceutics13101577","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T21:38:09Z","timestamp":1632865089000},"page":"1577","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Administration and Therapeutic Drug Monitoring of \u03b2-lactams and Vancomycin in Critical Care Units in Colombia: The ANTIBIOCOL Study"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3869-8195","authenticated-orcid":false,"given":"Yuli V.","family":"Fuentes","sequence":"first","affiliation":[{"name":"Master\u2019s Student in Epidemiology, Faculty of Medicine, Universidad de La Sabana, Ch\u00eda 140013, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5510-4742","authenticated-orcid":false,"given":"Jhosep","family":"Blanco","sequence":"additional","affiliation":[{"name":"Evidence-Based Therapeutics Group, Department of Clinical Pharmacology, Faculty of Medicine, Universidad de La Sabana and Cl\u00ednica Universidad de La Sabana, Ch\u00eda 140013, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8804-0274","authenticated-orcid":false,"given":"Diana Marcela","family":"D\u00edaz-Quijano","sequence":"additional","affiliation":[{"name":"Health Research Group, Department of Epidemiology, Faculty of Medicine, Universidad de La Sabana, Ch\u00eda 140013, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6292-8742","authenticated-orcid":false,"given":"Sharon","family":"Lechtig-Wasserman","sequence":"additional","affiliation":[{"name":"Evidence-Based Therapeutics Group, Department of Clinical Pharmacology, Faculty of Medicine, Universidad de La Sabana and Cl\u00ednica Universidad de La Sabana, Ch\u00eda 140013, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3030-4836","authenticated-orcid":false,"given":"Hans","family":"Liebisch-Rey","sequence":"additional","affiliation":[{"name":"Evidence-Based Therapeutics Group, Department of Clinical Pharmacology, Faculty of Medicine, Universidad de La Sabana and Cl\u00ednica Universidad de La Sabana, Ch\u00eda 140013, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"D\u00edaz-Pinilla","sequence":"additional","affiliation":[{"name":"Evidence-Based Therapeutics Group, Department of Clinical Pharmacology, Faculty of Medicine, Universidad de La Sabana and Cl\u00ednica Universidad de La Sabana, Ch\u00eda 140013, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0921-8973","authenticated-orcid":false,"given":"Peter","family":"Vergara-Ramirez","sequence":"additional","affiliation":[{"name":"Evidence-Based Therapeutics Group, Department of Clinical Pharmacology, Faculty of Medicine, Universidad de La Sabana and Cl\u00ednica Universidad de La Sabana, Ch\u00eda 140013, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa-Helena","family":"Bustos","sequence":"additional","affiliation":[{"name":"Evidence-Based Therapeutics Group, Department of Clinical Pharmacology, Faculty of Medicine, Universidad de La Sabana and Cl\u00ednica Universidad de La Sabana, Ch\u00eda 140013, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Garzon, V., Bustos, R.H., and Pinacho, D.G. (2020). Personalized Medicine for Antibiotics: The Role of Nanobiosensors in Therapeutic Drug Monitoring. J. Pers. Med., 10.","DOI":"10.3390\/jpm10040147"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"Kang","year":"2009","journal-title":"Korean J. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Osorio, C., Garzon, L., Jaimes, D., Silva, E., and Bustos, R.H. (2021). Impact on Antibiotic Resistance, Therapeutic Success, and Control of Side Effects in Therapeutic Drug Monitoring (TDM) of Daptomycin: A Scoping Review. Antibiotics, 10.","DOI":"10.3390\/antibiotics10030263"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2125.2011.04080.x","article-title":"Therapeutic drug monitoring of antimicrobials","volume":"73","author":"Roberts","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1007\/s00134-013-3088-4","article-title":"Clinical implications of antibiotic pharmacokinetic principles in the critically ill","volume":"39","author":"Udy","year":"2013","journal-title":"Intensive Care Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/phar.2505","article-title":"A guide to therapeutic drug monitoring of beta-lactam antibiotics","volume":"41","author":"Fratoni","year":"2021","journal-title":"Pharmacotherapy"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1007\/s11096-018-0634-8","article-title":"Evaluation of risk factors for vancomycin-induced nephrotoxicity","volume":"40","author":"Park","year":"2018","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1128\/AAC.45.9.2460-2467.2001","article-title":"Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: Prospective multicenter randomized study","volume":"45","author":"Wysocki","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00134-013-3187-2","article-title":"Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: A randomised controlled trial","volume":"40","author":"Carrette","year":"2014","journal-title":"Intensive Care Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ijantimicag.2017.01.009","article-title":"Impact of \u03b2-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy","volume":"49","author":"Economou","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.burns.2015.01.001","article-title":"Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients","volume":"41","author":"Fournier","year":"2015","journal-title":"Burn. J. Int. Soc. Burn. Injuries"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lechtig-Wasserman, S., Liebisch-Rey, H., Diaz-Pinilla, N., Blanco, J., Fuentes-Barreiro, Y.V., and Bustos, R.H. (2021). Carbapenem Therapeutic Drug Monitoring in Critically Ill Adult Patients and Clinical Outcomes: A Systematic Review with Meta-Analysis. Antibiotics, 10.","DOI":"10.3390\/antibiotics10020177"},{"key":"ref_15","first-page":"957","article-title":"Is high-dose \u03b2-lactam therapy associated with excessive drug toxicity in critically ill patients?","volume":"82","author":"McDonald","year":"2016","journal-title":"Minerva Anestesiol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Richter, D.C., Dietrich, M., Lalev, L.D., Schmitt, F.C.F., Fiedler, M.O., Bruckner, T., Stoerzinger, D., Chiriac, U., Klein, S., and Hackert, T. (2021). Prolonged Infusion of \u03b2-lactams Decreases Mortality in Patients with Septic Shock: A Retrospective before-and-after Study. Antibiotics, 10.","DOI":"10.20944\/preprints202105.0668.v1"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40560-020-00490-z","article-title":"Prolonged versus intermittent beta-lactam antibiotics intravenous infusion strategy in sepsis or septic shock patients: A systematic review with meta-analysis and trial sequential analysis of randomized trials","volume":"8","author":"Kondo","year":"2020","journal-title":"J. Intensive Care"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","article-title":"Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Societe Francaise de Pharmacologie et Therapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Societe Francaise d\u2019Anesthesie et Reanimation-SFAR)","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit. Car."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","article-title":"Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"71","author":"Rybak","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ye, Z.K., Li, C., and Zhai, S.D. (2014). Guidelines for therapeutic drug monitoring of vancomycin: A systematic review. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0099044"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.diagmicrobio.2014.04.007","article-title":"How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?","volume":"79","author":"Felton","year":"2014","journal-title":"Diagn Microbiol. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40262-012-0020-y","article-title":"Benchmarking therapeutic drug monitoring software: A review of available computer tools","volume":"52","author":"Fuchs","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13054-018-2155-1","article-title":"Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients","volume":"22","author":"Veiga","year":"2018","journal-title":"Crit. Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S588","DOI":"10.1093\/infdis\/jix326","article-title":"The Value That Infectious Diseases Physicians Bring to the Healthcare System","volume":"216","author":"McQuillen","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.medmal.2019.07.005","article-title":"Impact of the French Infectious Diseases Society\u2019s (SPILF) proposals for shorter antibiotic therapies","volume":"49","author":"Macheda","year":"2019","journal-title":"Med. Mal. Infect."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jama.283.6.749","article-title":"A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin","volume":"283","author":"Marrie","year":"2000","journal-title":"JAMA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.medmal.2019.02.001","article-title":"Streamlined guidelines for antibiotic therapies are required for greater efficacy","volume":"49","author":"Roger","year":"2019","journal-title":"Med. Mal. Infect."},{"key":"ref_28","first-page":"1639","article-title":"Measuring Appropriate Antimicrobial Use: Attempts at Opening the Black Box","volume":"63","author":"Spivak","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10096-012-1803-7","article-title":"A survey of beta-lactam antibiotics and vancomycin dosing strategies in intensive care units and general wards in Belgian hospitals","volume":"32","author":"Buyle","year":"2013","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.cmi.2016.04.019","article-title":"The ANTIBIOPERF study: A nationwide cross-sectional survey about practices for beta-lactam administration and therapeutic drug monitoring among critically ill patients in France","volume":"22","author":"Charmillon","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jcrc.2020.08.027","article-title":"The ONTAI study-a survey on antimicrobial dosing and the practice of therapeutic drug monitoring in German intensive care units","volume":"60","author":"Liebchen","year":"2020","journal-title":"J. Crit. Care"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1093\/jac\/dkv165","article-title":"The ADMIN-ICU survey: A survey on antimicrobial dosing and monitoring in ICUs","volume":"70","author":"Tabah","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/jac\/dkt523","article-title":"An international, multicentre survey of beta-lactam antibiotic therapeutic drug monitoring practice in intensive care units","volume":"69","author":"Wong","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.medmal.2016.01.010","article-title":"Preparing and administering injectable antibiotics: How to avoid playing God","volume":"46","author":"Longuet","year":"2016","journal-title":"Med. Mal. Infect."},{"key":"ref_35","unstructured":"Porta, M. (2016). A Dictionary of Epidemiology, Oxford University Press. [6th ed.]."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11096-019-00938-9","article-title":"A survey of antibiotic administration practices involving patients with sepsis in UK critical care units","volume":"42","author":"Barton","year":"2020","journal-title":"Int J. Clin. Pharm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/CCM.0000000000004326","article-title":"Continuous Versus Intermittent Infusion of Vancomycin and the Risk of Acute Kidney Injury in Critically Ill Adults: A Systematic Review and Meta-Analysis","volume":"48","author":"Flannery","year":"2020","journal-title":"Crit Care Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jhin.2019.09.003","article-title":"Current status of antimicrobial stewardship programmes in Korean hospitals: Results of a 2018 nationwide survey","volume":"104","author":"Kim","year":"2020","journal-title":"J. Hosp. Infect."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/10\/1577\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:06:38Z","timestamp":1760166398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/10\/1577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["pharmaceutics13101577"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13101577","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]}}}